Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 294, Issue 4, 2008, Pages

  Anderson, David E ^a,b   Fedorova, Olga V ^a   Morrell, Christopher H ^a,c   Longo, Dan L ^b   Kashkin, Vladimir A ^a   Metzler, Jessica D ^b   Bagrov, Alexei Y ^a   Lakatta, Edward G ^a,b  

^a Laboratory of Cardiovascular Science   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c LOYOLA UNIVERSITY MARYLAND   (United States)

Author keywords

Hypertension; Marinobufagenin; Ouabain

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; MARINOBUFAGENIN; OUABAIN; SODIUM CHLORIDE;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; SODIUM EXCRETION; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE; URINE LEVEL;

ADULT; AGE FACTORS; AGED; AGING; BLOOD PRESSURE; BODY MASS INDEX; BUFANOLIDES; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION; LINEAR MODELS; MIDDLE AGED; MODELS, BIOLOGICAL; NATRIURESIS; OUABAIN; SODIUM CHLORIDE, DIETARY; SODIUM-POTASSIUM-EXCHANGING ATPASE; SYSTOLE; TIME FACTORS; UP-REGULATION;

EID: 41749087357     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00782.2007     Document Type: Article

References (35)

1. Anderson DE, Scuteri A, Agalakova N, Parsons DJ, Bagrov AY. Racial differences in resting end-tidal CO2 and circulating sodium pump inhibitor. Am J Hypertens 14: 761-767, 2001.
2. Anderson DE, Parsons BA, McNeely JD, Miller ER. Resting respiratory rate predicts salt sensitivity: results of a clinical feeding trial in women. J Am Soc Hypertens 1: 256-263, 2007.
3. Bagrov AY, Fedorova OV, Austin-Lane JL, Dmitrieva RI, Anderson DE. Endogenous marinobufagenin-like immunoreactive factor and Na,K ATPase inhibition during voluntary hypoventilation. Hypertension 26: 781-788, 1995.
4. Bagrov AY, Fedorova OV. Cardenolide and bufadinenolide ligands of the sodium pump. How they work together in NaCl sensitive hypertension. Front Biosci 10: 2250-2256, 2005.
5. Baker PF, Blaustein MP, Hodgkin AL, Steinhardt RA. The influence of calcium on sodium efflux in squid axons. J Physiol 200: 431-458, 1969.
6. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am J Physiol Cell Physiol 232: C165-C173, 1977.
7. Fedorova OV, Lakatta EG, Bagrov AY. Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of Dahl rats. Circulation 102: 3009-3014, 2000.
8. Fedorova OV, Kolodkin NI, Agalakova NI, Lakatta EG, Bagrov AY. Marinobufagenin, an endogenous α-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats. Hypertension 37: 462-466, 2001.
9. + ATPase inhibition by a putative endogenous ligand, marinobufagenin. Hypertension 39: 298-302, 2002.
10. 1-sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation 105: 1122-1127, 2002.
11. Fedorova OV, Agalakova NI, Talan MI, Lakatta EG, Bagrov AY. Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signaling in NaCl-loaded Dahl-S rats. J Hypertens 23: 1515-1523, 2005.
12. Fedorova OV, Kolodkin NI, Agalakova NI, Namikas AR, Bzhelyansky A, St-Louis J, Lakatta EG, Bagrov AY. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens 23: 835-842, 2005.
13. Fedorova OV, Agalakova NI, Lakatta EG, Bagrov AY. ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta. Hypertension 48: 1160-1168, 2006.
14. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 30: 886-896, 1997.
15. +-ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 290: R529-R535, 2006.
16. Gates PE, Tanaka H, Hiatt WR, Seals DR. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 44: 35-41, 2004.
17. Goto A, Yamada K, Yagi N, Yoshioka M, Sugimoto T. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 44: 377-399, 1992.
18. Haddy FJ, Pamnani MB, Clough DL. Humoral factors and the sodium-potassium pump in volume expanded hypertension. Life Sci 24: 2105-2117, 1979.
19. Haddy FJ, Pamnani MB. Role of ouabain-like factors and Na-K-ATPase inhibitors in hypertension-some old and recent findings. Clin Exp Hypertens 20: 499-508, 1998.
20. Khaw KT, Barrett-Connor E. The association between blood pressure, age and dietary sodium and potassium: a population study. Circulation 77: 53-61, 1988.
21. Lakatta EG. Mechanisms of hypertension in the elderly. J Am Geriatr Soc 37: 780-790, 1989.
22. Manunta P, Hamilton BP, Hamlyn JM. Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol 290: R553-R559, 2006.
23. Manunta P, Citterio L, Lanzani C, Ferrandi M. Adducin polymorphism and the treatment of hypertension. Pharmacogenomics 8: 465-472, 2007.
24. Morrell CH, Pearson JD, Brant LJ. Linear transformations of linear mixed-effects models. Am Stat 51: 338-343, 1997.
25. Pechere-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens 17: 994-1001, 2004.
26. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. Age-adjusted standards for creatinine clearance. Ann Intern Med 84: 567-569, 1976.
27. Sacks FM, Svetkey LP, Vollmer MW, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller 3rd ER, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 344: 3-10, 2001.
28. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 293: C509-C536, 2007.
29. Vu HV, Ianosi-Irimie MR, Pridjian CA, Whitbred JM, Durst JM, Bagrov AY, Fedorova OV, Pridjian G, Puschett JB. Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 25: 520-528, 2005.
30. de Wardener HE, Clarkson EM. Concept of natriuretic hormone. Physiol Rev 65: 658-759, 1985.
31. de Wardener HE, MacGregor GA. Sodium and blood pressure. Curr Opin Cardiol 17: 360-367, 2002.
32. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 8, Suppl II: II127-II134, 1986.
33. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension 18: 67-71, 1991.
34. Weinberger MH. Salt sensitivity: does it play an important role in the pathogenesis and treatment of hypertension? Curr Opin Nephrol Hypertens 5: 2095-2098, 1996.
35. Ye T, Liu ZQ, Mu JJ, Fu FH, Yang J, Gao BL, Zhang XH. Blood pressure changes with age in salt sensitive teenagers. Clin Med Sci J 19: 248-251, 2004.